This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Listen to this manuscript’s
audio summary by
JACC Editor-in-Chief
Dr. Valentin Fuster.
J O U R N A L O F T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y V O L . 7 2 , N O . 2 1 , 2 0 1 8
ª 2 0 1 8 B Y T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y F O UN DA T I O N
P U B L I S H E D B Y E L S E V I E R
A Targeting Nanotherapy forAbdominal Aortic Aneurysms
A bdominal aortic aneurysm (AAA) is a leadingcause of mortality and morbidity in theelderly (1). Pathologically, infiltration of large
numbers of inflammatory cells (2), elevated levels ofmatrix metalloproteinases (MMPs) (3), overproducedreactive oxygen species (ROS) (4), intimal and medialcalcification (5), neovascularization (6), apoptosis ofvascular smooth muscle cells (VSMCs) (7), and degra-dation of elastic lamellae aorta (3) are involved in an-eurysms. Despite no symptoms before rupture,
N 0735-1097/$36.00
m the aDepartment of Pharmaceutics, College of Pharmacy, Third Milit
epartment of Cardiology, Southwest Hospital, Third Military Medical Univ
the National Natural Science Foundation of China (Nos. 81471774 & 817018
uthwest Hospital (No. SWH2016ZDCX1016), and the Science and Tech
Southwest Hospital (No. SWH2016LHYS-05). The authors have reported tha
this paper to disclose.
nuscript received January 22, 2018; revised manuscript received August
rupture of AAAs is often lethal, with mortality of85% to 90% (8).
Mechanical intervention, including open andendovascular repair, is currently the only effectivetreatment that can prevent aneurysm-related death(9). Unfortunately, open surgery is associated withperioperative mortality and morbidity (10). On theother hand, approximately 20% to 30% of patientswho undergo endovascular repair require reinter-vention within 5 years due to reperfusion and the
https://doi.org/10.1016/j.jacc.2018.08.2188
ary Medical University, Chongqing, China; and the
ersity, Chongqing, China. This study was supported
32), the Innovation Program for Key Technologies of
nology Innovation Program in Military Medicine
t they have no relationships relevant to the contents
Cheng et al. J A C C V O L . 7 2 , N O . 2 1 , 2 0 1 8
A Targeting Nanotherapy for Abdominal Aortic Aneurysms N O V E M B E R 2 7 , 2 0 1 8 : 2 5 9 1 – 6 0 5
2592
associated risk of aneurysm rupture (11). Inaddition, for small aneurysms and aneu-rysms with anatomic constraints, both repairmethods are not optimal strategies (8).Consequently, effective drugs that candecrease AAA expansion and prevent AAAsfrom rupture are imperative. Recent studiesindicated that synthetic inhibitors of MMPs(12) and angiotensin-converting enzyme (13)can suppress the expansion of experimentalAAAs. Rapamycin (RAP), an immunosup-pressant and an inhibitor of mammaliantarget of rapamycin, also prevented aneu-rysm growth in rats (14). Regardless ofpromising results in preclinical studies, noneof the existing drugs have provided benefi-cial effects in clinical trials (15). Additionally,administration of these drugs is generallyassociated with adverse effects due to theirnonspecific distribution. Also, poor watersolubility limits their clinical applications.Therefore, innovative strategies that canreduce side effects of antianeurysmal drugswhile maintaining or even potentiating theirefficacies are urgently needed to promoteclinical translation.
As is well documented, oxidative stress,resulting from overproduced ROS, is closelyassociated with AAA formation (4). On thebasis of this pathophysiological feature, wedeveloped a multifunctional nanotherapy fortargeted treatment of AAAs. By ligand andmacrophage cell membrane–mediated syn-ergistic targeting, the new nanotherapy caneffectively accumulate in AAAs and releasedrug molecules in response to high ROS inaneurysms.
SEE PAGE 2606
METHODS
Details of the materials and methods are available inthe Online Appendix.
SYNTHESIS OF A ROS-RESPONSIVE MATERIAL AND
PREPARATION OF DIFFERENT NANOPARTICLES.
A ROS-responsive material (oxidation-responsiveb-cyclodextrin material [OxbCD]) was synthesized bycovalently conjugating 4-(hydroxymethyl)phenyl-boronic acid pinacol ester (PBAP) onto b-cyclodextrin(16). A modified nanoprecipitation/self-assemblymethod was used to prepare different nanoparticles(NPs) (16). To prepare a ROS-responsive nanotherapycoated with macrophage cell membrane, cell mem-brane vesicles (CMVs) derived from macrophages
were first prepared (17), which were then coated ontothe cores of NPs by coextruding through a 200-nmpolycarbonate membrane.
IN VITRO HYDROLYSIS AND RELEASE TESTS.
In vitro hydrolysis of different NPs was conducted inphosphate-buffered saline with or without 1.0 mmol/lH2O2. The hydrolysis degree was calculated byquantifying the transmittance values at 500 nm atpredetermined time points. For in vitro release ex-periments, freshly prepared RAP nanotherapies wereplaced into dialysis tubing. At predetermined timeintervals, the RAP concentration in the release me-dium was quantified.
INTRACELLULAR UPTAKE STUDIES. RAW264.7mouse macrophages or VSMCs were seeded ontocoverslips in a 12-well plate. After incubation withCy5-labeled NPs for pre-defined time periods andstaining with 4,6-diamidino-2-phenylindole (DAPI),fluorescence images were acquired. In separate ex-periments, VSMCs and RAW264.7 cells were seeded ina 12-well plate and incubated with Cy5-labeled NPs.After 1, 2, or 8 h of incubation, fluorescence in-tensities in cells were analyzed by flow cytometry.
DETECTION OF CELL CALCIFICATION IN VSMCs.
VSMCs were seeded in a 24-well plate. After pre-treatment with different formulations for 24 h, cellswere induced with calcium and inorganic phosphorus(Ca/Pi) for 24 h. The cell calcification degree wasassessed by Alizarin Red staining. Besides directobservation, the calcium content and cell viability ofVSMCs were quantified.
QUANTIFICATION OF INTRACELLULAR ROS GENERATION
IN VSMCs. The intracellular ROS levels in VSMCsinduced by H2O2 were evaluated by dihydroethidium(DHE) staining. Cells were seeded onto coverslips in a12-well plate. After 24 h of incubation with differentformulations, cells were exposed to 400 mmol/l H2O2
for another 6 h. Fluorescence microscopy was per-formed after the nuclei were stained with DAPI. Inseparate studies, the intracellular ROS levels inVSMCs were quantified by flow cytometry.
IN VITRO APOPTOSIS ASSAY OF VSMCS. VSMCswere seeded in a 12-well plate. After 12 h of incuba-tion with various formulations, cells were treatedwith 400 mmol/l H2O2 for 6 h. Subsequently, apoptosisanalysis was performed by flow cytometry using aFITC Annexin V Apoptosis Detection Kit with 7-AAD(BioLegend, San Diego, California). Cell viability af-ter different treatments was also quantified.
ESTABLISHMENT OF AN EXPERIMENTAL AAA
MODEL IN RATS. Male Sprague-Dawley rats wereobtained from the Animal Center at the Third MilitaryMedical University (Chongqing, China). All animal
J A C C V O L . 7 2 , N O . 2 1 , 2 0 1 8 Cheng et al.N O V E M B E R 2 7 , 2 0 1 8 : 2 5 9 1 – 6 0 5 A Targeting Nanotherapy for Abdominal Aortic Aneurysms
2593
care and experiments were performed in accordancewith the Guide for the Care and Use of LaboratoryAnimals proposed by the National Institutes ofHealth. Local elastin damage in the abdominal aorticregion in rats was induced by perivascular applicationof calcium chloride (CaCl2). In all cases for the imag-ing and therapeutic studies, rats in the normal controlor AAA- group were surgically treated with saline,following the similar procedures.
IN VIVO TARGETING CAPABILITY OF DIFFERENT
NANOPARTICLES. Two weeks after AAA in rats wasinduced by CaCl2 infiltration, Cy7.5-labeled NPs wereadministered in randomly assigned rats via intrave-nous (IV) injection. At 8 h after different treatments,the thoracic aorta, abdominal aorta, and bilateral iliacarteries were harvested together for ex vivo imaginganalyses. In separate studies, the distribution ofnanoparticles in aneurysms was analyzed by immu-nofluorescence, after AAA rats were treated withdifferent Cy5-labeled NPs.
THERAPEUTIC EFFECTS OF NANOTHERAPIES IN
AAA RATS. AAA in rats was induced as aforemen-tioned. At day 2 or 10 after injury, nanotherapies wereIV injected in randomly assigned rats twice a week for3 weeks at 1.0 mg/kg of RAP. After treatment, theabdominal aortas were isolated for different qualita-tive and quantitative analyses.
STATISTICAL ANALYSIS. Statistical analysis wasperformed by SPSS 13.0 (IBM, Armonk, New York).Analyses of cellular uptake data were performed us-ing repeated measures analysis of variance in 2-wayanalysis with the least significant difference posthoc test, and the Mauchly’s test of sphericity wasused to evaluate heterogeneity of variances. Statisti-cal analyses in other cases were conducted using1-way analysis of variance with least significant dif-ference post hoc tests. p < 0.05 was considered to bestatistically significant.
RESULTS
DESIGN OF AN ADVANCED NANOTHERAPY. Fortargeted therapy of AAAs, we designed a ROS-responsive, integrin targeting, and macrophage-mimetic nanoplatform (Online Figure 1). The core ofthis nanoplatform consisted of an oxidation-responsive material, which is encased within a lipidshell anchored with polyethylene glycol (PEG) chainsto provide water solubility and long blood circulation.To enhance aneurysmal targeting, the shell of thisnanoplatform is further functionalized with a peptideligand and macrophage cell membrane (OnlineFigure 1A). After targeting to aneurysmal sites, this
nanoplatform can release therapeutic molecules upontriggering by ROS, thereby affording the desirableefficacy (Online Figure 1B).
DEVELOPMENT OF DIFFERENT RAP NANOTHERAPIES.
For the synthesized ROS-responsive material, eachOxbCD contained approximately 6 PBAP units (OnlineFigure 2A). Poly(D,L-lactide-co-glycolide) (PLGA), aU.S. Food and Drug Administration–approved biode-gradable polymer, was used as a nonresponsive ma-terial. OxbCD and PLGA NPs containing RAP wereprepared by nanoprecipitation (Figure 1A) (18), whichwere defined as OR NP and PR NP, respectively. Theobtained nanotherapies displayed a spherical shapeas observed by transmission electron microscopy(Figures 1B and 1C), with narrow size distribution.Both nanotherapies showed negative zeta-potential(Figure 1D). The average diameter was 197 � 3 mmand 167 � 4 nm, whereas the RAP content was 5.4 wt%and 7.8 wt% for PR NP and OR NP, respectively.
IN VITRO DRUG RELEASE OF NANOTHERAPIES. ForPR NP, <50% of total RAP was released from PR NPafter 72 h in phosphate-buffered saline with 0 or1.0 mmol/l H2O2 (Figure 1E). By contrast, RAP releasefrom OR NP was dramatically accelerated by1.0 mmol/l H2O2. Nearly complete RAP release(w96%) from OR NP was found at 72 h, significantlyhigher than that without H2O2. This result agrees withthe hydrolysis behaviors of corresponding blank NPs(Online Figure 2B). These in vitro tests demonstratedROS-responsive release characteristics of OR NP.
CELLULAR UPTAKE OF VARIOUS NANOPARTICLES.
Using Cy5-labeled NPs derived from PLGA (PCy5 NP)or OxbCD (OCy5 NP) (Online Figures 2C and 2D), weexamined cellular uptake of NPs in rat VSMCs andRAW264.7 murine macrophages, since both VSMCsand macrophages are involved in the pathogenesis ofAAAs (2). Fluorescence observation showed that PCy5NP and OCy5 NP were internalized by VSMCs andmacrophages in a time-dependent manner (Figures 1Fand 1G). Even at 1 h, considerable fluorescent signalsin both cells were observed. Flow cytometric quanti-fication demonstrated remarkably enhanced intra-cellular accumulation of NPs with prolongedincubation (Figures 1H and 1I). Of note, both PLGA andOxbCD NPs exhibited low cytotoxicity in VSMCs(Online Figure 2E).
NANOTHERAPIES INHIBIT CA/PI-INDUCED
CALCIFICATION AND CELL DEATH IN VSMCs.
Vascular calcification has been considered as a riskfactor for rupture of AAAs (5). We evaluated in vitroanticalcification effects of nanotherapies in ratVSMCs. After exposure to Ca/Pi, Alizarin Red stainingshowed significant calcium deposition in VSMCs of
FIGURE 1 Fabrication, Characterization, and Cellular Uptake of Different NPs
A
NanoprecipitationSelf-assembly
PR NP
PLGA
RAP
DSPE-PEG
OxbCD
OR NP
NanoprecipitationSelf-assembly
B
200 nm
PR NP
15
10
5
0103102
Diameter (nm)101 104
20
Inte
nsity
(%)
C
200 nm
OR NP
15
10
5
0103102
Diameter (nm)101 104
20
25
Inte
nsity
(%)
D
–10
–20
–30
0 PR N
P
OR
NP
Zeta
-Pot
entia
l (m
V)
–40
E
120
90
60
150
Cum
ulat
ive
Rele
ase
of R
AP (%
)
30
00 60504030
Time (h)2010 70
PR NP at 0 mM H2O2
OR NP at 1.0 mM H2O2
OR NP at 0 mM H2O2
PR NP at 1.0 mM H2O2
FControl
PCy5 NP2 h1 h 8 h Control
OCy5 NP2 h1 h 8 h
GControl
PCy5 NP2 h1 h 8 h Control
OCy5 NP2 h1 h 8 h
H
100
80604020
0
Cy5
100
106104
PCy5 NP
102
Coun
ts
100
80604020
0
100
106104
OCy5 NP
102
300
200
100
0
2Time (h)
10
***
8
400
MFI
(x10
3 )
*****
PCy5 NP OCy5 NP0 h 1 h 2 h 8 h
I750
500
250
0
2Time (h)
10
***
8
1000
MFI
(x10
3 ) ******
PCy5 NP OCy5 NP0 h 1 h 2 h 8 h
100
80604020
0
Cy5
100
106104
PCy5 NP
102
Coun
ts
100
80604020
0
100
106104
OCy5 NP
102
(A) Schematic of RAP nanotherapies preparation. TEM images (left) and size distribution (right) of PLGA (B) and OxbCD (C) nanotherapies. (D) Zeta-potential values.
(E) In vitro release profiles of PR NP and OR NP. Fluorescence images illustrating internalized Cy5-labeled NPs in VSMCs (F) or macrophages (G). Scale bars indicate 20
mm. Flow cytometric curves (left) and quantification (right) of internalized NPs in VSMCs (H) or macrophages (I). Data are mean � SD (H, I, n ¼ 3). **p < 0.01; ***p <
PLGA ¼ poly(D,L-lactide-co-glycolide); PR NP ¼ PLGA-derived rapamycin nanotherapy; RAP ¼ rapamycin; TEM ¼ transmission electron microscopy; VSMCs ¼ vascular
smooth muscle cells.
Cheng et al. J A C C V O L . 7 2 , N O . 2 1 , 2 0 1 8
A Targeting Nanotherapy for Abdominal Aortic Aneurysms N O V E M B E R 2 7 , 2 0 1 8 : 2 5 9 1 – 6 0 5
2594
FIGURE 2 In Vitro Activities of Nanotherapies in VSMCs
AControl Model OxbCD NP RAP PR NP OR NP
1.5
1.0
0.5
2.0 ***
Rela
tive
Calc
ifica
tion
0.0
Cont
rol
PR N
PRA
PO
xbCD
NP
Mod
el
OR
NP
Cont
rol
PR N
PRA
PO
xbCD
NP
Mod
el
OR
NP
** ***
B C
90
60
30
120
Cell
Viab
ility
(%)
0
***
DControl Model OxbCD NP RAP PR NP OR NP Tempol
E2520
1015
5
30
MFI
(x10
3 )
Cont
rol
PR N
PRA
PO
xbCD
NP
Mod
el
OR
NPTe
mpo
l0
***
***
G
40
2030
10
50
Apop
totic
Cel
ls (%
)
Cont
rol
PR N
PRA
PO
xbCD
NP
Mod
el
OR
NPTe
mpo
l0
***
*** *
**
H
90
3060
120
Cell
Viab
ility
(%)
Cont
rol
PR N
PRA
PO
xbCD
NP
Mod
el
OR
NPTe
mpo
l0
****
FModel
0.6 11.0
65.2 23.2
OxbCD NP
0.5 6.6
72.8 20.1
RAP
1.0 14.2
75.6 9.2
PR NP
2.3 12.1
78.2 7.4
OR NP
0.2 1.1
97.0 1.7
Tempol
0.1 1.2
96.7 2.0
Control
0.1 1.2
97.7 1.0
Annexin V-FITC
7-AA
D
(A) Visualization of calcium deposition via Alizarin Red staining. Upper panel, digital photos; lower panel, microscopic images of VSMCs. Quantified calcium deposition
(B) and cell viability (C) of VSMCs. (D) Fluorescence images of DHE-stained VSMCs after H2O2 stimulation. Scale bars, 20 mm. (E) Quantified fluorescent intensities of
DHE showing intracellular ROS generation. Flow cytometric profiles (F) and quantitative data (G) of apoptotic VSMCs after induction with H2O2. (H) Cell viability after
different pre-treatments and stimulation with H2O2. Cells in the control group were treated with fresh medium. Data are mean � SD (n ¼ 3). *p < 0.05; **p < 0.01;
***p < 0.001. DHE ¼ dihydroethidium; ROS ¼ reactive oxygen species; other abbreviations as in Figure 1.
J A C C V O L . 7 2 , N O . 2 1 , 2 0 1 8 Cheng et al.N O V E M B E R 2 7 , 2 0 1 8 : 2 5 9 1 – 6 0 5 A Targeting Nanotherapy for Abdominal Aortic Aneurysms
2595
the model group (Figures 2A and 2B). Pre-treatmentwith RAP or nanotherapies dramatically reducedcalcification. OR NP–treated cells displayed thelowest calcium deposition. Furthermore, treatmentwith different RAP formulations protected VSMCsfrom Ca/Pi-induced cell death (Figure 2C), with themost efficacious effect for the OR NP group.
NANOTHERAPIES DECREASE H2O2-INDUCED ROS
GENERATION AND APOPTOSIS IN VSMCs. VSMCstreated with H2O2 showed notably increased intra-cellular ROS (Figure 2D). Pre-incubation with RAPformulations significantly reduced ROS. The respon-sive nanotherapy OR NP even completely inhibitedthe production of ROS, comparable to the effect ofTempol, a frequently used ROS scavenger. Thisobservation was affirmed by flow cytometric quanti-fication (Figure 2E, Online Figure 3). Accordingly, ourresults demonstrated that the antioxidative stress
activity of RAP was notably potentiated by loadinginto nanocarriers, particularly for the responsive RAPnanotherapy.
Mechanistically, depletion of medial VSMCs byapoptosis contributes to the growth of AAAs (7). H2O2
could induce significant cell apoptosis (Figures 2F and2G). Pre-incubation with RAP formulations attenu-ated H2O2-induced VSMCs apoptosis. At the samedose of RAP, the responsive nanotherapy exhibitedthe most beneficial effect. Consistently, OR NP mosteffectively maintained VSMCs viability (Figure 2H).Consequently, OR NP can significantly inhibit H2O2-induced VSMCs apoptosis by reducing intracellularROS generation.
IN VIVO TARGETING CAPABILITY OF NANOPARTICLES.
In vivo targeting of NPs to aneurysmal aortas wasexamined in rats with CaCl2-induced AAAs, usingCy7.5-labeled NPs based on PLGA (PCy7.5 NP) or
Cheng et al. J A C C V O L . 7 2 , N O . 2 1 , 2 0 1 8
A Targeting Nanotherapy for Abdominal Aortic Aneurysms N O V E M B E R 2 7 , 2 0 1 8 : 2 5 9 1 – 6 0 5
2596
OxbCD (OCy7.5 NP) (Online Figure 4A). At 8 h after IVinjection, fluorescent signals were clearly observed atthe injury site of abdominal aortas isolated from AAArats (Figure 3A). Quantitative analysis showed signif-icantly higher accumulation of OCy7.5 NP than that ofPCy7.5 NP. By contrast, the abdominal aortas fromnormal rats treated with fluorescent NPs displayed nosignificant fluorescence. Besides, distribution of NPsin liver, spleen, and lung were observed (OnlineFigure 4B). Fluorescence observation on cry-osections confirmed the accumulation of NPs inaneurysmal aortas (Figure 3B), with more significantfluorescence in the OCy5 NP group. These resultsdemonstrated that IV administered NPs are able topassively target aneurysmal aortas.
TREATMENT OF AAAs BY NANOTHERAPIES IN
RATS. We examined in vivo efficacy of RAP nano-therapies in AAA rats. Treatments by IV injectionwere conducted at day 2 after CaCl2 stimulation(Online Figure 5A). Hematoxylin and eosin–stainedsections showed that the maximal diameter ofinfrarenal abdominal aortas in the model group wassignificantly enlarged (Online Figure 5B, Figures 3Cand 3D). Among different formulations, OR NP mosteffectively reduced the aneurysm diameter. AlizarinRed–stained sections revealed substantially lowercalcification after treatment with RAP formulations(Online Figure 5B, Figure 3C), particularly in the ORNP group (Figure 3E). Similarly, Verhoeff-Van Giesonstaining indicated the broken and damaged elasticlamina in the model and blank OxbCD NP groups,whereas elastin was preserved after therapy with RAPand nanotherapies. Again, OR NP prevented elastindegradation to a much better degree than PR NP(Online Figure 5B, Figure 3C).
Immunohistochemistry analyses showed that thelevels of MMP-2 and MMP-9, 2 important MMPsinvolved in AAAs (3), were remarkably decreased byRAP formulations, especially OR NP (Figure 3F, OnlineFigure 5C). Consistently, quantification by Westernblotting revealed their expression in aneurysmalaortas was most significantly decreased after OR NPtreatment (Figures 3G and 3H). Compared with bothmodel and OxbCD NP groups, infiltration of CD68þ
macrophages in the adventitia and ruptured mediawas attenuated by OR NP (Figure 3F, Online Figure 6).CD31 staining indicated the most intact endotheliumfor OR NP–treated rats. These results demonstratedthat the ROS-responsive nanotherapy can substan-tially inhibit the development of AAAs.
To address the mechanisms responsible for thebeneficial effects of nanotherapies, the levels of
representative inflammatory cytokines and chemo-kines in aortas were determined. The expressions oftumor necrosis factor (TNF)-a, interferon (IFN)-g,interleukin (IL)-1b, and monocyte chemoattractantprotein (MCP)-1 were dramatically reduced in bothnanotherapy groups, when compared with the modelgroup (Online Figure 7A). Also, nanotherapy-treatedgroups showed notably lower levels of ROS in aneu-rysmal tissues (Online Figures 7B to 7D).
In a separate study, OR NP was administered at day10 after CaCl2-induced injury. In this case, beneficialefficacies were also achieved, as implicated bysignificantly inhibited aneurysmal expansion andcalcification, remarkably decreased elastin degrada-tion, as well as notably reduced inflammatoryresponse and oxidative stress (Online Figure 8).
Taken together, RAP nanotherapies, especially ORNP can significantly prevent the progression of AAAsin rats, by reducing expressions of MMPs and proin-flammatory cytokines/chemokines, inhibiting calcifi-cation, and lowering ROS generation.
ENGINEERING OF A CRGDFK-FUNCTIONALIZED
RESPONSIVE NANOTHERAPY. To develop a nano-therapy with enhanced targeting, we functionalizedthe responsive nanotherapy with cRGDfK, a cyclo-peptide ligand that can target neovessels via bindingwith avb3 integrin (19). cRGDfK was first covalentlylinked with a lipid-PEG conjugate DSPE-PEG (OnlineFigure 9). The ROS-responsive RAP nanotherapywith cRGDfK decoration (referred to as ROR NP)(Figure 4A), was also prepared by the aforementionednanoprecipitation method. ROR NP showed a core-shell spherical shape (Figures 4B and 4C), with themean diameter of 179 � 3 nm and zeta-potentialof �25 mV. The RAP content in ROR NP was 8.1 wt%.ROR NP also displayed H2O2-triggered drug releasekinetics (Figure 4D). This result is consistent with thehydrolysis profiles of blank NPs (Online Figure 10A).
IN VITRO EVALUATIONS OF THE CRGDFK-DECORATED
NANOTHERAPY. Blank OxbCD NPs with or withoutcRGDfK showed comparable cell viability in VSMCs(Online Figure 10B). Using Cy5-labeled fluorescent NP(ROCy5 NP) (Online Figure 11A), we found time-dependent internalization of cRGDfK-coated NP inmacrophages and VSMCs (Online Figures 11B to 11E,Figures 4E and 4F). Of note, cRGDfK-functionalizedNP exhibited significantly higher cellular uptake ascompared with the undecorated control in both cells.
Although both ROS-responsive nanotherapiessignificantly inhibited Ca/Pi-induced calcification andcell death in VSMCs (Figures 4G to 4I), ROR NPshowed more beneficial effects. As compared with OR
FIGURE 3 In Vivo Targeting and Efficacies of Nanotherapies in AAA Rats
BSaline PCy5 NP OCy5 NP
A
Salin
e
PCy7
.5 N
P
OCy
7.5
NP
PCy7
.5 N
P
OCy
7.5
NP
AAA+ AAA+AAA–
0.4
1.00.80.6
1.2Ra
dian
t Eff
icie
ncy
(x10
7 , p/s
/cm
2 /sr/
μμW/c
m2 )
AAA+ AAA+AAA–
6
4
2
0
Salin
e
OCy
7.5
NPPC
y7.5
NP
OCy
7.5
NPPC
y7.5
NP
8
Aver
age
Fluo
resc
ence
Inte
nsity
(x10
7 , p/s
/cm
2 /sr/
μW/c
m2 )
***
**
C
H&E
VVG
Aliz
arin
Red
Normal RAP PR NPOxbCD NPModel OR NPD
1.82.1
1.51.2
2.4
Diam
eter
(mm
)
**
*
E
0.20.3
0.10.0
Norm
al
PR N
PO
R NPRA
PO
xbCD
NP
Mod
elNo
rmal
PR N
PO
R NPRA
PO
xbCD
NP
Mod
el
0.4
The
Calc
ium
Con
tent
(mm
ol/g
Pro
tein
) ****
F
MM
P-2
MM
P-9
CD31
CD68
Normal RAP PR NPOxbCD NPModel OR NP
H
1.0
2.01.5
0.50.0
2.5
Rela
tive
MM
P-2
Cont
ents ***
1.0
2.01.5
0.50.0
Norm
al
PR N
PO
R NPRA
PO
xbCD
NP
Mod
el
Norm
al
PR N
PO
R NPRA
PO
xbCD
NP
Mod
el
2.5
Rela
tive
MM
P-9
Cont
ents ***
**
G
Norm
al
MMP-2
β-actin
MMP-9
β-actin
RAP
PR N
P
Oxb
CD N
P
Mod
el
OR
NP
(A) Ex vivo images (left) and quantitative analysis (right) showing the accumulation of PCy7.5 NP or OCy7.5 NP in normal (AAA-) or aneurysmal (AAAþ) aortas at 8 h
after intravenous injection. (B) Fluorescence images illustrating PCy5 NP or OCy5 NP in abdominal aortas. Scale bars indicate 20 mm. (C) Histological sections indicating
the maximal diameter, calcium deposition, and elastin degradation in aneurysmal aortas. The mean maximal diameter (D) and calcium contents (E) of abdominal aortas.
(F) Immunohistochemistry analysis of the levels of MMP-2 and MMP-9 as well as the counts of macrophages and vascular endothelial cells in aneurysmal aortas.
Western blot bands (G) and quantitative analysis (H) of MMP-2 and MMP-9 levels. In the normal group, healthy rats were treated with saline. Data are mean � SD
VVG ¼ Verhoeff-Van Gieson; other abbreviations as in Figure 1.
J A C C V O L . 7 2 , N O . 2 1 , 2 0 1 8 Cheng et al.N O V E M B E R 2 7 , 2 0 1 8 : 2 5 9 1 – 6 0 5 A Targeting Nanotherapy for Abdominal Aortic Aneurysms
2597
FIGURE 4 Engineering of a ROS-Responsive, cRGDfK Targeting Nanotherapy ROR NP
MModel ROR NPOR NP
NLK
201510
5
25
MFI
(x10
3 )
0
OR
NP
Mod
el
ROR
NP
***
***80604020
100
Cell
Viab
ility
(%)
0
OR
NP
Mod
el
ROR
NP
**45
30
15
60
Apop
totic
Cel
ls (%
)
0
OR
NP
Mod
el
ROR
NP
*
***
I
80604020
100
Cell
Viab
ility
(%)
0
OR
NP
Mod
el
ROR
NP
**
H
0.9
0.6
0.3
1.2
0.0
OR
NP
Mod
el
ROR
NP
***
J0.8 12.8
50.2
Model
36.2
0.2 1.7
96.6
OR NP
1.5
0.0 0.0
98.7
ROR NP
1.3
Annexin V-FITC
7-AA
D
A B
200 nm
15
10
5
0101 103
Size (nm)102 104
20
Inte
nsity
(%) –10
0
–20
ROR NP
Zeta
-Pot
entia
l (m
V)
–30
C D
120
90
60
30
0605040
Time (h)302010 070
150
Cum
ulat
ive
Rele
ase
of R
AP (%
)
ROR NP at 1.0 mM H2O2
ROR NP at 0 mM H2O2
OR NP at 0 mM H2O2
OR NP at 1.0 mM H2O2
EControl
ROCy
5 NP
OCy
5 NP
1 h 2 h 8 h
2Time (h)
10
300
150
0
450M
FI (x
103 )
8
******
***
OCy5 NPROCy5 NP
F GModel ROR NPOR NP
(A) Schematic of ROR NP. (B) TEM image (left) and size distribution (right) of ROR NP. Zeta-potential (C) and in vitro release profiles (D) of ROR NP. (E) Fluorescence
images of VSMCs incubated with ROCy5 NP or OCy5 NP for different periods of time. (F) Quantified fluorescence intensities by flow cytometry. (G) Ca/Pi-induced
calcification of VSMCs pre-treated with different formulations. Upper panel, digital photos; lower panel, microscopy images of VSMCs. Quantification of the calcium
content (H) and cell viability (I) of VSMCs pre-treated with different formulations and induced with Ca/Pi. Flow cytometric profiles (J) and quantitative analysis (K) of
apoptotic cells as well as cell viability (L) of VSMCs pre-treated with nanotherapies and stimulated with H2O2. (M) Fluorescence images showing intracellular ROS
generation. (N) Fluorescence intensity of DHE quantified by flow cytometry. Scale bars indicate 20 mm. Data are mean � SD (n ¼ 3). *p < 0.05; **p < 0.01; ***p <
0.001. cRGDfK ¼ a cyclic peptide ligand; ROCy5 NP ¼ Cy5-labeled OxbCD nanoparticle with cRGDfK decoration; ROR NP ¼ a ROS-responsive, cRGDfK targeting RAP
nanotherapy; other abbreviations as in Figures 1 and 2.
Cheng et al. J A C C V O L . 7 2 , N O . 2 1 , 2 0 1 8
A Targeting Nanotherapy for Abdominal Aortic Aneurysms N O V E M B E R 2 7 , 2 0 1 8 : 2 5 9 1 – 6 0 5
2598
J A C C V O L . 7 2 , N O . 2 1 , 2 0 1 8 Cheng et al.N O V E M B E R 2 7 , 2 0 1 8 : 2 5 9 1 – 6 0 5 A Targeting Nanotherapy for Abdominal Aortic Aneurysms
2599
NP, ROR NP more significantly suppressed apoptosis,maintained cell viability, and decreased ROS genera-tion in VSMCs induced by H2O2 (Figures 4J to 4N,Online Figure 11F). Together, these results demon-strated that ROR NP can further potentiate the ther-apeutic effects of RAP by enhancing intracellulardelivery of drug molecules via receptor-mediatedendocytosis.
IN VIVO TARGETING AND EFFICACIES OF THE
CRGDFK-FUNCTIONALIZED NANOTHERAPY IN
RATS. At 8 h after IV injection of Cy7.5-labeledcRGDfK-coated NP (ROCy7.5 NP) in AAA rats (OnlineFigures 12A and 12B), ex vivo imaging showedevident fluorescent signals at aneurysmal sites(Figure 5A), distinctly different from those of normalrats. The fluorescent intensity of cRGDfK-coated NPwas 2.5-fold higher than that of cRGDfK-deficient NP.Nevertheless, nearly similar distribution profiles werefound in major organs (Online Figure 12C). Furtherimmunofluorescence examination indicated theconsiderable distribution of Cy5-labeled NP in thediseased sites of abdominal aortas (Figure 5B, OnlineFigure 13). Notably, cRGDfK-coated NP displayedrelatively high accumulation in both intimal andmedial regions. These results substantiated that theaneurysmal targeting capacity of responsive NP canbe notably improved by decoration with cRGDfK.
In vivo efficacies were then assessed in AAA rats(Online Figure 14A). ROR NP more significantlyreduced the maximum diameter of abdominal aortas,decreased calcification, and suppressed elastindegradation, when compared with the control nano-therapy OR NP (Online Figure 14B, Figures 5C to 5E). Ascompared with OR NP, ROR NP had more prominenteffects on decreasing the MMP-2 and MMP-9 levels,lowering macrophage infiltration, and preservingendothelial integrity (Figures 5F to 5H, OnlineFigures 14C and 14D). Likewise, ROR NP more signifi-cantly reduced the levels of TNF-a, IFN-g, IL-1b,MCP-1,and ROS in abdominal aortas (Figure 5I, OnlineFigure 15). Of note, the efficacious discrepancy of ORNP between this and aforementioned studies shouldbe due to different batches of model animals. Collec-tively, ROR NP can more significantly prevent thedevelopment of AAAs by actively targeting aneurysms.
A ROS-RESPONSIVE NANOTHERAPY SIMULTANEOUSLY
FUNCTIONALIZED WITH CRGDFK AND MACROPHAGE
CELL MEMBRANE. To further improve targeting capa-bility of the cRGDfK-decorated nanotherapy, it wasfunctionalized by macrophage cell membrane(Figure 6A), in view of the fact that local macrophageinfiltration is one of the main pathological mecha-nisms of AAA (2). As a proof of concept, rat alveolar
macrophage NR8383 cells were used. CMVs(w300 nm) were first prepared from NR8383 cells(Figure 6B). By coextruding CMVs and ROR NP, amacrophage-mimetic, active targeting, and ROS-responsive RAP nanotherapy (CROR NP) was fabri-cated, exhibiting a typical core–shell structure(Figure 6B). CROR NP showed negative zeta-potential,comparable to that of CMVs (Figure 6C). CROR NPdisplayed narrow size distribution (Figure 6D), withan average diameter of 190 nm. The successfulcoating of macrophage cell membrane was confirmedby profiling protein components. In this case, CRORNP showed similar protein bands as CMVs (Figure 6E).The RAP content in CROR NP was 4.1 wt%. In com-parison to that of ROR NP, RAP release from CROR NPwas slightly delayed, resulting from the presence ofouter membrane that acts as a diffusion barrier fordrug molecules (Figure 6F). This is consistent with thehydrolysis behaviors of blank NPs (OnlineFigure 16A). These results demonstrated the suc-cessful development of a cRGDfK and macrophagecell membrane-functionalized ROS-responsivenanotherapy.
IN VIVO TARGETING AND EFFICACIES OF CROR NP
IN RATS. Using cRGDfK/cell membrane functional-ized and Cy7.5-labeled NP (CROCy7.5 NP) (OnlineFigure 16B), in vivo targeting capability was exam-ined. Compared with the control ROCy7.5 NP, stron-ger fluorescent signals were detected for CROCy7.5NP at AAA sites (Figure 6G). Almost no fluorescenceappeared in aortas of normal rats receiving the samedose of CROCy7.5 NP. Also, fluorescent signals wereobserved in liver, spleen, and lung for the ROCy7.5 NPand CROCy7.5 NP groups (Online Figure 16C).Different NPs exhibited similar pharmacokineticprofiles post-IV injection in healthy or AAA rats(Online Figures 16D and 16E). As compared with otherNPs, CROCy7.5 NP displayed prolonged blood circu-lation. The elimination half-life of CROCy7.5 NP inAAA rats was slightly longer than that in healthy rats(Online Figure 16F).
Using Cy5-labeled and cell membrane–coated NP(CROCy5 NP) (Online Figure 16G) and the controlROCy5 NP, we also observed the localization of bothNPs in aneurysms of abdominal aortas (Figure 6H).CROCy5 NP exhibited notably stronger fluorescentsignals, agreeing with ex vivo images. These resultscollectively demonstrated that macrophage cellmembrane cloaking can additionally enhance theactive targeting capacity endowed by cRGDfKfunctionalization.
After IV treatment (Online Figure 17A), CROR NPshowed greater antianeurysmal activity than ROR NP,
FIGURE 5 In Vivo Targeting and Therapeutic Activities of ROR NP in AAA Rats
Salin
e
OCy
7.5
NP
ROCy
7.5
NP
OCy
7.5
NP
ROCy
7.5
NP
AAA+ AAA+AAA–
30
20
10
40
0
**
******
Aver
age
Fluo
resc
ence
Inte
nsity
(x10
7 , p/s
/cm
2 /sr/
μμW/c
m2 )
1.0
0.8
0.6
1.2
Radi
ant E
ffici
ency
(x10
7 , p/s
/cm
2 /sr/
μW/c
m2 )
0.4
Saline
OCy7.5 NP
ROCy7.5 NP
OCy7.5 NP
ROCy7.5 NP
AAA+ AAA+AAA-
A BOCy5 NP
α-S
MA
CD68
ROCy5 NP
DAPI
CD68
Cy5
DAPI
α-SMA
Cy5
G
ROR NP
RO NPModel
MMP-2
β-actin
β-actin
MMP-9
H
ROR
NP
RO N
P
Mod
el
1.20.90.60.3
1.5
Rela
tive
MM
P-2
Leve
ls
0.0
***
***
ROR
NP
OR
NP
Mod
el
1.20.90.60.3
1.5
Rela
tive
MM
P-9
Leve
ls
0.0
****
***
ROR
NP
OR
NP
Mod
el
40302010
50
IFN-
γ (ng
/g P
rote
in)
0
*
***
ROR
NP
OR
NP
Mod
el
30
20
10
40
MCP
-1 (n
g/g
Prot
ein)
0
*
***
I
ROR
NP
OR
NP
Mod
el
201510
5
25
TNF-
α(n
g/g
Prot
ein)
0
*
***
ROR
NP
OR
NP
Mod
el
90
60
30
120
IL-1
β(n
g/g
Prot
ein)
0
**
***
CH&E
ROR
NPO
R NP
Mod
el
Alizarin Red VVGF
MMP-2
ROR
NPO
R NP
Mod
el
MMP-9 CD68 CD31
E
ROR
NP
OR
NP
Mod
el
0.3
0.2
0.4
The
Calc
ium
Con
tent
(mm
ol/g
Pro
tein
)
0.0
*****
*
D
ROR
NP
OR
NP
Mod
el
2.0
1.5
2.5
Diam
eter
(mm
)
1.0
*****
*
(A) Ex vivo images (left) and histograms (right) showing accumulated ROCy7.5 NP or OCy7.5 NP in aneurysmal aortas. (B) Immunofluorescence analysis of
localized ROCy5 NP in aneurysms. Scale bars indicate 20 mm. (C) Hematoxylin and eosin, Alizarin Red, or VVG stained histological sections of aneurysmal
aortas. Quantification of the maximal diameter (D) and calcium contents (E) of abdominal aortas. (F) Immunohistochemistry analyses of aneurysmal aortas.
Representative Western blot bands (G) and quantitative analysis (H) of MMP-2 and MMP-9 levels in abdominal aortas. (I) The levels of proinflammatory
cytokines/chemokines in abdominal aortas. Data are mean � SD (n ¼ 3). *p < 0.05; **p < 0.01; ***p < 0.001. ROCy7.5 NP ¼ Cy7.5-labeled OxbCD
nanoparticle decorated with cRGDfK; SMA ¼ smooth muscle actin; other abbreviations as in Figures 1 to 4.
Cheng et al. J A C C V O L . 7 2 , N O . 2 1 , 2 0 1 8
A Targeting Nanotherapy for Abdominal Aortic Aneurysms N O V E M B E R 2 7 , 2 0 1 8 : 2 5 9 1 – 6 0 5
2600
FIGURE 6 Development of CROR NP and Its In Vivo Targeting Capability
EC
Zeta
-Pot
entia
l (m
V)
–5
–10
–15
0
–20
CROR NPCMV
CMV
CRO
R NP
CRO
R NP
CROCy5 NP
DAPI
DAPI
Cy5
Cy5
CD68
ROCy5NP
CD68
α-SM
A
α-SMA
CMV
Mar
ker
ROP
NP
Inte
nsity
(%)
25
51015
20
0101 102 103
Size (nm)104
DB
A
F
120
90
60
30
0605040
Time (h)3020100 70
150
Cum
ulat
ive
Rele
ase
of R
AP (%
)
CROR NP at 1.0 mM H2O2
CROR NP at 0.0 mM H2O2
ROR NP at 0.0 mM H2O2
ROR NP at 1.0 mM H2O2
Aver
age
Fluo
resc
ence
Inte
nsity
(x10
8 , p/s
/cm
2 /sr/
μμW/c
m2 )
15
9
12
3
***
6
0
AAA+
Salin
eRO
Cy7.
5 NP
CRO
Cy7.
5 NP
ROCy
7.5
NPCR
OCy
7.5
NP***
*
AAA+AAA–
Salin
e
ROCy
7.5
NP
CRO
Cy7.
5 NP
ROCy
7.5
NP
CRO
Cy7.
5 NP
AAA+ AAA+AAA-
Radi
ant E
ffic
ienc
y(x
107 ,
p/s/
cm2 /
sr/μ
W/c
m2 )
1.5
2.0
1.0
G H
(A) Schematic of CROR NP. TEM images (B) and zeta-potential values (C) of CMVs and CROR NP. (D) Size distribution of CROR NP. (E) SDS-polyacrylamide gel
electrophoresis analysis of proteins on ROR NP, CMVs, and CROR NP. (F) In vitro release profiles of ROR NP or CROR NP. (G) Ex vivo images (left) and quantification
(right) of accumulated ROCy7.5 NP or CROCy7.5 NP in aneurysmal aortas. (H) Immunofluorescence observation of localized ROCy5 NP or CROCy5 NP. Scale bars indicate
20 mm. Data are mean � SD (n ¼ 3). *p < 0.05; ***p < 0.001. CMV ¼ cell membrane vesicle; CROR NP ¼ a ROS-responsive, cRGDfK targeted, and macrophage cell
membrane-coated rapamycin nanotherapy; CROCy5 NP ¼ Cy5-labeled OxbCD nanoparticle with cRGDfK and cell membrane coating; CROCy7.5 NP ¼ Cy7.5-labeled
OxbCD nanoparticle with cRGDfK and cell membrane coating; other abbreviations as in Figures 1 to 5.
J A C C V O L . 7 2 , N O . 2 1 , 2 0 1 8 Cheng et al.N O V E M B E R 2 7 , 2 0 1 8 : 2 5 9 1 – 6 0 5 A Targeting Nanotherapy for Abdominal Aortic Aneurysms
2601
in terms of attenuating the expansion of the aorticdiameter, preventing calcification, decreasing elastindegradation, and maintaining endothelial integrity,as well as dampening inflammation and loweringoxidative stress in aneurysmal tissues (Figure 7,Online Figures 17 and 18). The potentiated therapeu-tic effects of CROR NP were correlated with improvedtargeting after macrophage membrane cloaking.
IN VIVO SAFETY STUDIES. Safety tests were per-formed in rats (Online Figures 19 and 20). During14 days of inspection, normal behaviors were
observed for all rats. All examined animals displayedcomparable body weight gain and the organ index.We did not find remarkable changes in representativehematological parameters in nanotherapy-treatedgroups. No abnormal variations in typical bio-markers associated with hepatic and kidney functionswere detected for different groups. Likewise, we didnot observe injuries or infiltration of inflammatorycells in hematoxylin and eosin–stained sections ofmajor organs. These preliminary data indicated thatdifferent RAP nanotherapies are safe for IVadministration.
(A) Hematoxylin and eosin, Alizarin Red, and VVG stained histopathological sections of aneurysmal aortas. The quantified maximal diameter (B) and calcium contents
(C) of abdominal aortas. (D) Immunohistochemistry analyses of MMP-2 and MMP-9 levels, the macrophage content, and the vascular endothelial integrity. Western
blot bands (E) and quantitative data (F) of MMP-2 and MMP-9. (G) The levels of TNF-a, IFN-g, 1L-1b, and MCP-1 in abdominal aortas. Data are mean � SD (n ¼ 3). *p <
0.05; **p < 0.01; ***p < 0.001. Abbreviations as in Figures 1 to 6.
Cheng et al. J A C C V O L . 7 2 , N O . 2 1 , 2 0 1 8
A Targeting Nanotherapy for Abdominal Aortic Aneurysms N O V E M B E R 2 7 , 2 0 1 8 : 2 5 9 1 – 6 0 5
2602
DISCUSSION
Despite worldwide efforts over the past decades,there remain no effective drugs that can prevent thegrowth of aneurysms and delay aneurysm rupture inthe clinical setting (8,15,20). To develop an effectivenanotherapy for aneurysms, we established a hierar-chical functionalization approach, using RAP as acandidate drug, for which clinical applications havebeen limited due to its adverse effects, such asimmunosuppression and increased lipid levels (21).Therefore, targeted delivery strategies that canreduce side effects of RAP while maintaining or even
amplifying its efficacy are desperately required(Central Illustration).
According to abnormally increased ROS in aneu-rysms (4), we first constructed a ROS-responsivenanoplatform using an oxidation-labile materialOxbCD to achieve triggerable drug delivery. TheOxbCD-derived nanotherapy OR NP can release RAPupon triggering by high levels of ROS. By internali-zation and responsively releasing RAP, OR NP effec-tively attenuated Ca/Pi-induced calcification inVSMCs and significantly inhibited intracellular ROSgeneration and cell apoptosis induced by H2O2. NPsbased on OxbCD were considerably accumulated in
CENTRAL ILLUSTRATION Targeted Treatment of AAA by a Multifunctional Nanotherapy
Cheng, J. et al. J Am Coll Cardiol. 2018;72(21):2591–605.
A hierarchically engineered, ROS-responsive, integrin targeting, and macrophage-mimetic rapamycin nanotherapy can efficaciously prevent the development of AAAs
by effectively targeting aneurysms after intravenous delivery. CROR NP ¼ a ROS-responsive, cRGDfK targeted, and macrophage cell membrane-coated rapamycin
J A C C V O L . 7 2 , N O . 2 1 , 2 0 1 8 Cheng et al.N O V E M B E R 2 7 , 2 0 1 8 : 2 5 9 1 – 6 0 5 A Targeting Nanotherapy for Abdominal Aortic Aneurysms
2603
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Overproduction of ROS in aneurysmal tissue might
serve as a molecular basis for targeted treatment. In
preliminary studies in vitro and in vivo, a ROS-
responsive nanoparticle, in combination with a
peptide ligand for integrin and macrophage cell
membranes, released rapamycin molecules in
response to the inflammatory microenvironment,
slowing abdominal aortic aneurysm progression.
TRANSLATIONAL OUTLOOK: Additional preclini-
cal studies are needed to confirm the therapeutic
benefit of targeted nanotherapy with rapamycin or
other antiproliferative agents and assess potential
toxicity during long-term treatment as a prelude to
clinical trials.
Cheng et al. J A C C V O L . 7 2 , N O . 2 1 , 2 0 1 8
A Targeting Nanotherapy for Abdominal Aortic Aneurysms N O V E M B E R 2 7 , 2 0 1 8 : 2 5 9 1 – 6 0 5
2604
aneurysms of AAA rats. This was achieved by themicrodefects in the destructed aneurysmal wall andthe damaged endothelial layer (14,22). In addition,neovessels in the media and adventitia mightcontribute to the accumulation of NPs in aneurysms(23). Moreover, ROS-triggered oxidation of OxbCDgenerates phenylboronic acid that can adhere to cellsor extracellular matrix at inflamed sites (24). Theseeffects collectively accounted for the high targetingefficiency of OxbCD NP. Consistently, the responsivenanotherapy displayed more desirable efficacy thanthat of the PLGA nanotherapy.
To further enhance targeting efficiency of theresponsive nanotherapy, we functionalized OR NP bysurface decoration with a cyclic peptide ligandcRGDfK. The cRGDfK-functionalized nanotherapyROR NP showed significantly potentiated in vitro ac-tivities in VSMCs. Also, cRGDfK coating increased theaccumulation of NPs in aneurysms in rats, therebyleading to additionally enhanced in vivo efficacies.Our results for the first time demonstrated thatcRGDfK can be used for targeted therapy of AAAs.
Finally, a macrophage-mimetic approach was usedto functionalize the cRGDfK-coated nanotherapy.Coating via cell membranes is an effective strategy toenhance delivery efficiency of various nanovehicles(25,26). Considering the critical role of macrophagesin the pathogenesis of AAAs (2), macrophage mem-brane was used to cloak cRGDfK-functionalizedresponsive NPs. We found that surface coating withmacrophage membrane further promoted aneurysmtargeting of cRGDfK-armed OxbCD NP, resulting fromhomotypic and heterotypic cell adhesion mechanisms(27). The macrophage-like recruitment effect mightalso contribute to the increased delivery efficiency atAAA sites (2). Correspondingly, the macrophage-mimetic, cRGDfK targeting nanotherapy CROR NPinhibited the progression of AAAs to a significantlygreater extent than ROR NP without membranecoating. Importantly, preliminary in vivo tests sub-stantiated that our nanotherapies displayed goodsafety profile after IV administration. In practice,based on screening and ultrasound surveillance ofaneurysm size, ROS might be used as biomarkers todetermine the right time point for treatment withnanotherapies. Also, these nanotherapies can becombined with other traditional anti-aneurysmaldrugs to prevent aneurysm formation. To addressmacrophage cell membrane limitations for trans-lation, the plasma membrane–derived proteins
responsible for aneurysm targeting will be incorpo-rated into the lipid shell of ROR NP in follow-upstudies (28).
STUDY LIMITATIONS. The therapeutic benefits andsafety profiles of our targeting nanotherapies need tobe examined in different animal models of AAAs, withlong-term treatment. Furthermore, whether this tar-geting strategy can be generalized to other cardio-vascular drugs remains to be addressed.
CONCLUSIONS
We developed a ROS-triggerable, aneurysmal target-ing nanotherapy via a hierarchical functionalizationstrategy, according to the pathophysiology of aneu-rysms. By effective delivery of the loaded therapeuticmolecules to diseased aortic sites, this nanotherapyefficaciously prevented aneurysm expansion in AAArats.
ADDRESS FOR CORRESPONDENCE: Prof. HouyuanHu, Department of Cardiology, Southwest Hospital,Third Military Medical University, 30 Gaotanyan MainStreet, Chongqing 400038, China. E-mail:[email protected]. OR Prof. Jianxiang Zhang,Department of Pharmaceutics, College of Pharmacy,Third Military Medical University, 30 Gaotanyan MainStreet, Chongqing 400038, China. E-mail: [email protected].
J A C C V O L . 7 2 , N O . 2 1 , 2 0 1 8 Cheng et al.N O V E M B E R 2 7 , 2 0 1 8 : 2 5 9 1 – 6 0 5 A Targeting Nanotherapy for Abdominal Aortic Aneurysms
2605
RE F E RENCE S
1. Klink A, Hyafil F, Rudd J, et al. Diagnosticand therapeutic strategies for small abdominalaortic aneurysms. Nat Rev Cardiol 2011;8:338–47.
2. Raffort J, Lareyre F, Clément M, Hassen-Khodja R, Chinetti G, Mallat Z. Monocytes andmacrophages in abdominal aortic aneurysm. NatRev Cardiol 2017;14:457–71.
3. Kadoglou NP, Liapis CD. Matrix metal-loproteinases: contribution to pathogenesis,diagnosis, surveillance and treatment of abdom-inal aortic aneurysms. Curr Med Res Opin 2004;20:419–32.
4. Emeto TI, Moxon JV, Au M, Golledge J. Oxida-tive stress and abdominal aortic aneurysm: po-tential treatment targets. Clin Sci 2016;130:301–15.
5. Buijs RV, Willems TP, Tio RA, et al. Calcificationas a risk factor for rupture of abdominal aorticaneurysm. Eur J Vasc Endovasc Surg 2013;46:542–8.
6. Holmes DR, Liao S, Parks WC, Thompson RW.Medial neovascularization in abdominal aortic an-eurysms: a histopathologic marker of aneurysmaldegeneration with pathophysiologic implications.J Vasc Surg 1995;21:761–71.
8. Kent KC. Abdominal aortic aneurysms. N Engl JMed 2014;371:2101–8.
9. Patel R, Sweeting MJ, Powell JT,Greenhalgh RM. Endovascular versus open repairof abdominal aortic aneurysm in 15-years’ follow-up of the UK Endovascular Aneurysm Repair trial 1(EVAR trial 1): a randomised controlled trial. Lan-cet 2016;388:2366–74.
10. Zettervall SL, Soden PA, Buck DB, et al. Sig-nificant regional variation exists in morbidity andmortality following repair of abdominal aorticaneurysm. J Vasc Surg 2017;65:1305–12.
11. Buck DB, van Herwaarden JA,Schermerhorn ML, Moll FL. Endovascular treat-ment of abdominal aortic aneurysms. Nat RevCardiol 2014;11:112–23.
12. Nosoudi N, Nahar-Gohad P, Sinha A, et al.Prevention of abdominal aortic aneurysm pro-gression by targeted inhibition of matrix metal-loproteinase activity with batimastat-loadednanoparticles. Cir Res 2015;117:e80–9.
13. Liao S, Miralles M, Kelley BJ, Curci JA,Borhani M, Thompson RW. Suppression of exper-imental abdominal aortic aneurysms in the rat bytreatment with angiotensin-converting enzymeinhibitors. J Vasc Surg 2001;33:1057–64.
14. Shirasu T, Koyama H, Miura Y, Hoshina K,Kataoka K, Watanabe T. Nanoparticles effectivelytarget rapamycin delivery to sites of experimentalaortic aneurysm in rats. PLoS One 2016;11:e0157813.
15. Lederle FA. Abdominal aortic aneurysm: stillno pill. Ann Intern Med 2013;159:852–3.
16. Dou Y, Chen Y, Zhang X, et al. Non-proin-flammatory and responsive nanoplatforms fortargeted treatment of atherosclerosis. Bio-materials 2017;143:93–108.
17. Cao H, Dan Z, He X, et al. Liposomes coatedwith isolated macrophage membrane can targetlung metastasis of breast cancer. ACS Nano 2016;10:7738–48.
18. Feng S, Hu Y, Peng S, et al. Nanoparticlesresponsive to the inflammatory microenvironmentfor targeted treatment of arterial restenosis. Bio-materials 2016;105:167–84.
19. Ye Y, Chen X. Integrin targeting for tumoroptical imaging. Theranostics 2011;1:102–26.
20. Golledge J, Norman PE. Current status ofmedical management for abdominal aortic aneu-rysm. Atherosclerosis 2011;217:57–63.
21. Dou Y, Guo J, Chen Y, et al. Sustained deliveryby a cyclodextrin material-based nanocarrier po-tentiates antiatherosclerotic activity of rapamycin
via selectively inhibiting mTORC1 in mice.J Control Release 2016;235:48–62.
22. Bailey TG, Perissiou M, Windsor M, et al. Ef-fects of acute exercise on endothelial function inabdominal aortic aneurysm patients. Am J PhysiolHeart Circ Physiol 2018;314:H19–30.
23. Choke E, Thompson MM, Dawson J, et al.Abdominal aortic aneurysm rupture is associatedwith increased medial neovascularization andoverexpression of proangiogenic cytokines. Arte-rioscler Thromb Vasc Biol 2006;26:2077–82.
24. Zhang Q, Tao H, Lin Y, et al. A superoxidedismutase/catalase mimetic nanomedicine fortargeted therapy of inflammatory bowel disease.Biomaterials 2016;105:206–21.
25. Hu CM, Fang RH, Wang KC, et al. Nanoparticlebiointerfacing by platelet membrane cloaking.Nature 2015;526:118–21.
26. Parodi A, Quattrocchi N, van de Ven AL, et al.Synthetic nanoparticles functionalized with bio-mimetic leukocyte membranes possess cell-likefunctions. Nat Nanotechnol 2013;8:61–8.
27. Rusciano D, Welch DR, Burger MM. Homotypicand heterotypic cell adhesion in metastasis. In: .In: Rusciano D, Welch DR, Burger MM, editors.Laboratory Techniques in Biochemistry and Mo-lecular Biology: Cancer Metastasis: ExperimentalApproaches. 1st edition, Volume 29. Amsterdam,the Netherlands: Elsevier Science, 2000:9–64.
28. Molinaro R, Corbo C, Martinez JO, et al. Bio-mimetic proteolipid vesicles for targeting inflamedtissues. Nat Mater 2016;15:1037.
KEY WORDS aneurysm, inflammation,nanotherapy, reactive oxygen species,targeting
APPENDIX For an expanded Methodssection as well as supplemental figures, pleasesee the online version of this paper.